Table 2.
Anthropometric and laboratory characteristics in the sample divided by Tanner’s stage (and approximate age) and gender.
| Tanner’s Stage I–II–III (Approximatively 12–15 Years) |
Tanner’s Stage IV–V (Approximatively > 15 Years) |
Tanner’s Stage: I–II–III vs. IV–V p Values |
|||||
|---|---|---|---|---|---|---|---|
| All (151) |
F (85) |
M (66) |
All (40) |
F (18) |
M (22) |
||
| Age, years | 13.5 (1.33) | 12.9 (1.3) | 12.6(1.3) | 15.9 (1.1) | 15.9 (1.3) | 16 (0.9) | 0.0001 |
| BMI, kg/sqm | 27.1 (4.2) | 27 (24–29) | 27.1 (24–29.5) | 29.8 (5.6) | 30 (25–33) | 28.8 (25–31) | 0.01 |
| WC, cm (IQR) | 84 (78–92) | 83 (78–92) | 83 (77–90.5) | 88 (78–97) | 87 (76–96) | 88 (81–97) | 0.04 |
| Uric acid, mg/dL | 5.2 (1.6) | 5.4 (1.6) | 5 (1.5) | 5.7 (1.6) | 5.3 (1.9) | 6 (1.2) | 0.14 |
| ALT, UI/L (IQR) | 59.7 (32–75.5) | 63 (33–78) | 55 (31–73) | 73 (28–96) | 85 (32–130) | 65 (28–78) | 0.08 |
| AST, UI/L (IQR) | 43 (27–52.5) | 44 (30–56) | 41.5 (26–49) | 45 (25–58) | 57 (24–67) | 39.5 (25–44.7) | 0.65 |
| GGT, UI/L (IQR) | 23.6 (15–27) | 25 (15–30) | 22 (14–25) | 32 (14–39) | 39 (31–18) | 26 (13–28) | 0.01 |
| Total-cholesterol, mg/dL (IQR) | 158 (132–178) | 165 (145–189) | 149 (123–169) | 161 (131–180) | 173 (131–216) | 151 (132–165) | 0.66 |
| HDL, mg/dL (IQR) | 46 (38–48.5) | 44.6 (39–49) | 47 (36–48) | 45 (36–48) | 46 (36–53) | 45 (35–44) | 0.82 |
| Triglycerides, mg/dL (IQR) | 104 (69–117) | 109 (97–122) | 99 (59–110) | 126 (89–168) | 125 (90–170) | 127 (89–163) | 0.05 |
| Glucose, mg/dL (IQR) | 83.6 (76–90) | 83 (76–89) | 84 (77–93) | 80 (76–86) | 85 (77–92) | 78 (71–83) | 0.13 |
| Insulin, μUI/ML (IQR) | 17 (10–24) | 19 (10–25.5) | 16 (10–21) | 18(10–24) | 22 (11–29) | 15 (10–19) | 0.71 |
| HOMA-IR (IQR) | 3.7 (2–4.9) | 3.9 (2.2–4.9) | 3.4 (2–5) | 3.8 (2–4.5) | 4.9 (2.8–6.9) | 3.1 (1.8–4) | 0.81 |
| DBP, mmHg (IQR) | 67 (60–74) | 67 (59–79) | 67.5 (61–73) | 66 (60–73) | 70 (68–75) | 63 (58–68) | 0.49 |
| SBP, mmHg (IQR) | 110 (101–118) | 110.5 (102–118) | 111 (102–115) | 111.5 (103–120) | 110 (105–118) | 112 (102–120) | 0.62 |
| TNF-a | 40 (7–47) | 41 (7–22.5) | 36.5(12–59) | 55.2 (43–89) | 44.5 (30–49) | 41 (33–78) | 0.06 |
| IL-6 | 26 (18–31.2) | 24 (19–29.5) | 27 (18.5–32) | 36.5 (25–50) | 25 (21–35) | 39 (26–49) | 0.13 |
| GH, ng/mL (IQR) | 10.2 (8–11) | 10.5(3.2) | 10 (8–11) | 10 (8–11) | 8.1 (7.5–11) | 10.4 (2–11.3) | 0.67 |
| IGF1, ng/mL(IQR) | 272 (198–345) | 267 (198–305) | 279 (208–347) | 268 (198–345) | 233 (164–305) | 395 (125–205) | 0.81 |
| IGFBP-3, µg/mL (IQR) | 2.4 (1.5–3.2) | 2.4 (1.5–3.2) | 2.4 (1.5–3.2) | 2.2 (1.5–2.8) | 2.2 (1.4–2.6) | 2.3 (1.6–2.9) | 0.5 |